Detalhe da pesquisa
1.
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
Lancet
; 402(10413): 1648-1659, 2023 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37778358
2.
Sutimlimab in Cold Agglutinin Disease.
N Engl J Med
; 384(14): 1323-1334, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33826820
3.
Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.
Am J Hematol
; 98(8): 1246-1253, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246953
4.
Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study.
Ann Hematol
; 101(10): 2169-2177, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35999387
5.
Pure red cell aplasia accompanied by COVID-19 successfully treated using cyclosporine.
J Infect Chemother
; 28(2): 304-307, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34772624
6.
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Kidney Int
; 97(6): 1287-1296, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32299680
7.
[Frontline clinical practice for thrombotic thrombocytopenic purpura].
Rinsho Ketsueki
; 61(9): 1331-1337, 2020.
Artigo
em Japonês
| MEDLINE | ID: mdl-33162533
8.
Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study.
Ann Hematol
; 103(5): 1803, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38519606
9.
Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Clin Exp Nephrol
; 23(1): 112-121, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30039480
10.
Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Clin Exp Nephrol
; 23(1): 65-75, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29959568
11.
[Rituximab for treatment of immune thrombocytopenia and thrombotic thrombocytopenic purpura].
Rinsho Ketsueki
; 60(5): 480-487, 2019.
Artigo
em Japonês
| MEDLINE | ID: mdl-31168017
12.
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results.
Haematologica
; 107(7): 1698-1702, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35172561
13.
TTP and aHUS: new insights.
Rinsho Ketsueki
; 58(5): 530-536, 2017.
Artigo
em Japonês
| MEDLINE | ID: mdl-28592771
14.
Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.
Kidney Int
; 99(5): 1244, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33892867
15.
Clinical guides for atypical hemolytic uremic syndrome in Japan.
Clin Exp Nephrol
; 20(4): 536-543, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27422619
16.
Clinical guides for atypical hemolytic uremic syndrome in Japan.
Pediatr Int
; 58(7): 549-55, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27460397
17.
Exciting investigator-initiated clinical trials.
Rinsho Ketsueki
; 57(10): 2145-2150, 2016.
Artigo
em Japonês
| MEDLINE | ID: mdl-27795524
18.
Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296.
Kidney Int
; 98(6): 1621, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33276869
19.
Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
BMC Health Serv Res
; 15: 2, 2015 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-25609557
20.
[Consensus report on the management of immune thrombocytopenia in pregnancy].
Rinsho Ketsueki
; 56(10): 2086-91, 2015 Oct.
Artigo
em Japonês
| MEDLINE | ID: mdl-26458448